Thane Wettig
Förmögenhet: 208 784 $ per 2026-08-31
Förmögenhet: 208 784 $ per 2026-08-31
Thane Wettig is Chief Executive Officer & Director at Kyntra Bio, Inc. since 2023.
Former roles include Chief Commercial Officer at Intarcia Therapeutics, Inc. and Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Education includes undergraduate and MBA degrees from Washington University in St. Louis.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
KYNTRA BIO, INC. 0,66 % | 2026-09-06 | 26 836 ( 0,66 % ) | 208 784 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| KYNTRA BIO, INC. | Verkställande Direktör | 2023-07-23 |
| Företag | Position | Slut |
|---|---|---|
Lilly Diabetes | Företagsledare/Principal | 2009-01-01 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Washington University in St. Louis
Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Health Technology |
Lilly Diabetes |
Välj din utgåva
All finansiell information anpassad till den nationella nivån